
    
      This is an open label, single arm, phase II investigator initiated clinical trial, evaluating
      efficacy and safety of Polatuzumab vedotin added to a modified infusional dose adjusted
      R-EPOCH like regimen, given on an inpatient basis, every 21 days, in subjects with Richter's
      Transformation.
    
  